



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: **Yu, et al.**

Application Number: 09/589,288

Group Art Unit: 1647

Filed: June 8, 2000

Examiner: Bunner, B.

Title: **Methods of Treatment Using Antibodies to Neutrokin-alpha (as amended)** Atty. Docket No. PF343P3C5

**AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111**

Commissioner for Patents  
Alexandria, VA 22313-1450

**RECEIVED**  
DEC 08 2003  
TECH CENTER 1600/2900

Sir:

In response to the Official Action mailed June 3, 2003 (Paper No. 16), Applicants request that the following amendments and remarks be entered into the above-identified application. Applicants submit concurrently herewith:

- (a) Declaration under 37 C.F.R. § 1.132 by David Hilbert with Exhibits A (Curriculum Vitae of David Hilbert) and B (Abbas et al., *Cellular and Molecular Immunology* (W.B. Saunders Company: Philadelphia) 1991, pp. 362 and 365);
- (b) Exhibit 1: Waldmann, TA, (2003) "Immunotherapy: Past, Present and Future" *Nature Medicine* 9:269-277;
- (c) Second Supplemental Information Disclosure Statement Pursuant to 37 C.F.R. § 1.56 and 1.97(c), (with a revised Form PTO/SB/08 and copies of references C1-C10);
- (d) Petition For a Three-Month Extension of Time Under 37 C.F.R. § 1.136(a);  
and
- (e) Fee Transmittal Sheet.

Amendments to the Specification begin on page 2.

Amendments to the Claims begin on page 4.

Remarks begin on page 11.